Should I buy or sell Instil Bio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TIL shares. View TIL analyst ratings or view top-rated stocks .

What is Instil Bio's stock price target for 2024?

3 Wall Street analysts have issued twelve-month price targets for Instil Bio's stock. Their TIL share price targets range from $18.00 to $54.00. On average, they expect the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 245.8% from the stock's current price. View analysts price targets for TIL or view top-rated stocks among Wall Street analysts .

How have TIL shares performed in 2024?

Instil Bio's stock was trading at $7.62 at the beginning of the year. Since then, TIL shares have increased by 36.6% and is now trading at $10.41. View the best growth stocks for 2024 here .

Are investors shorting Instil Bio?

Instil Bio saw a decline in short interest in March. As of March 31st, there was short interest totaling 8,800 shares, a decline of 41.3% from the March 15th total of 15,000 shares. Based on an average daily trading volume, of 28,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the company's shares are short sold. View Instil Bio's Short Interest .

When is Instil Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TIL earnings forecast .

How were Instil Bio's earnings last quarter?

Instil Bio, Inc. (NASDAQ:TIL) released its quarterly earnings results on Thursday, March, 21st. The company reported ($1.99) earnings per share for the quarter.

When did Instil Bio's stock split?

Instil Bio's stock reverse split before market open on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Instil Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC) , Saul Centers (BFS) , Virtus LifeSci Biotech Products ETF (BBP) , Bellevue Healthcare (BBH) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , ArrowMark Financial (BANX) , Yamana Gold (AUY) , A. O. Smith (AOS) , Sphere 3D (ANY) and Andersons (ANDE) .

When did Instil Bio IPO?

Instil Bio (TIL) raised $250 million in an IPO on Friday, March 19th 2021. The company issued 13,900,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.

How do I buy shares of Instil Bio?

Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TIL

Instil Bio (TIL) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free TIL Stock Alerts

$10.41

-0.18 (-1.70%)

(As of 03:59 PM ET)

Compare

Today's Range: $10.34
▼
$10.55
50-Day Range: $10.33
▼
$12.59
52-Week Range: $6.07
▼
$14.00

Volume: 7,459 shs
Average Volume: 27,521 shs
Market Capitalization: $67.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Get Instil Bio alerts:

Instil Bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 245.8% Upside
$36.00 Price Target
Short Interest: Healthy
0.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.30
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($5.54) to ($7.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.98 out of 5 stars

Medical Sector

311th out of 919 stocks

Biological Products, Except Diagnostic Industry

45th out of 152 stocks

3.3

Analyst's Opinion

Consensus Rating
Instil Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Instil Bio has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.22% of the float of Instil Bio has been sold short.
Short Interest Ratio / Days to Cover
Instil Bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Instil Bio has recently decreased by 41.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Instil Bio does not currently pay a dividend.
Dividend Growth
Instil Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TIL.

1.5

News and Social Media Coverage

News Sentiment
Instil Bio has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Instil Bio this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for TIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Instil Bio to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Instil Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
54.70% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Instil Bio are expected to decrease in the coming year, from ($5.54) to ($7.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Instil Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Instil Bio is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Instil Bio has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Instil Bio Stock (NASDAQ:TIL)

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

TIL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TIL Stock News Headlines

April 17, 2024 | msn.com

Instil Bio (TIL) Price Target Decreased by 23.15% to 28.22

April 12, 2024 | msn.com

Jefferies cuts Instil Bio to hold, cites drug discontinuation

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

March 22, 2024 | seekingalpha.com

Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14

March 21, 2024 | globenewswire.com

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 12, 2024 | ft.com

A Very Private School — Charles Spencer’s privileged but painful education

March 11, 2024 | theguardian.com

Jon Cruddas: ‘Labour has to rediscover its moral purpose’

February 24, 2024 | benzinga.com

Instil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and Dates

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

February 21, 2024 | sg.yahoo.com

Alexei Navalny death latest: Putin brings new criminal case against critic’s brother as mother pleads for body

February 19, 2024 | msn.com

How RSS textbooks are reshaping Indian history and science under Modi

February 16, 2024 | thestreet.com

Instil Bio Inc.

February 5, 2024 | msn.com

Boeing in ‘last chance saloon’, Emirates boss says

January 17, 2024 | msn.com

Instil Bio hits four-month high on rising volumes

January 16, 2024 | finance.yahoo.com

Instil Bio Announces Strategic Update

December 16, 2023 | msn.com

Instil Bio (TIL) Price Target Increased by 1650.00% to 71.40

December 13, 2023 | investorplace.com

TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023

December 13, 2023 | investorplace.com

TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023

December 5, 2023 | marketwatch.com

Instil Bio Shares Fall 7% After Reverse Split News

December 5, 2023 | finance.yahoo.com

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

November 14, 2023 | msn.com

Instil Bio Non-GAAP EPS of -$0.16 misses by $0.01

November 13, 2023 | finance.yahoo.com

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023 | finance.yahoo.com

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

November 4, 2023 | morningstar.com

Instil Bio Inc TIL

September 24, 2023 | money.usnews.com

Instil Bio Inc

September 7, 2023 | markets.businessinsider.com

Truist Financial Remains a Hold on Instil Bio (TIL)

See More Headlines

Receive TIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TIL
CUSIP: N/A
CIK: 1625584
Web: www.tillcap.com
Phone: 972-499-3350
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.00
High Stock Price Target: $54.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +240.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($23.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-156,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -58.49%
Return on Assets: -41.58%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 15.23
Quick Ratio: 15.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $34.72 per share
Price / Book: 0.30

Miscellaneous

Outstanding Shares: 6,500,000
Free Float: 2,946,000
Market Cap: $68.80 million
Optionable: Optionable
Beta: 1.24

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Bronson Crouch (Age 51)
Chairman & CEO
Comp: $672.37k
Dr. Sandeep Laumas M.D. (Age 55)
CFO & Chief Business Officer
Comp: $489.14k
Dr. Mark E. Dudley Ph.D.
Chief Scientific Officer
Dr. Robert Hawkins MBBS
Ph.D., Head of Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Instil Bio stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TIL shares.
View TIL analyst ratings or view top-rated stocks.
What is Instil Bio's stock price target for 2024?: 3 Wall Street analysts have issued twelve-month price targets for Instil Bio's stock. Their TIL share price targets range from $18.00 to $54.00. On average, they expect the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 245.8% from the stock's current price.
View analysts price targets for TIL or view top-rated stocks among Wall Street analysts.
How have TIL shares performed in 2024?: Instil Bio's stock was trading at $7.62 at the beginning of the year. Since then, TIL shares have increased by 36.6% and is now trading at $10.41.
View the best growth stocks for 2024 here.
Are investors shorting Instil Bio?: Instil Bio saw a decline in short interest in March. As of March 31st, there was short interest totaling 8,800 shares, a decline of 41.3% from the March 15th total of 15,000 shares. Based on an average daily trading volume, of 28,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the company's shares are short sold.
View Instil Bio's Short Interest.
When is Instil Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TIL earnings forecast.
How were Instil Bio's earnings last quarter?: Instil Bio, Inc. (NASDAQ:TIL) released its quarterly earnings results on Thursday, March, 21st. The company reported ($1.99) earnings per share for the quarter.

When did Instil Bio's stock split?: Instil Bio's stock reverse split before market open on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Instil Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE).
When did Instil Bio IPO?: Instil Bio (TIL) raised $250 million in an IPO on Friday, March 19th 2021. The company issued 13,900,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.
How do I buy shares of Instil Bio?: Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TIL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial